ArticleJournal of experimental & clinical cancer research : CR2026
DNA base lesion-containing G-quadruplex mediates transcriptome reprogramming in EGFR-TKI resistance of non-small cell lung cancer.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundCancer cells, such as non-small cell lung cancer (NSCLC) cells, exhibit remarkable phenotypic plasticity and undergo epigenetic reprogramming, characteristics that enable them to evade targeted therapies. However, how NSCLC cells use epigenetic regulatory mechanisms (including endogenous DNA base damage) to drive transcriptome reprogramming and develop resistance to EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy remains unclear.
methodsWe employed an integrated multi-omics approach in erlotinib-sensitive and resistant NSCLC cells, including genome-wide mapping of abasic sites (AP sites) via Single-Strand Break Mapping at Nucleotide Genome Level-AP (SSiNGLe-AP), characterization of binding landscapes of 8-Oxoguanine DNA Glycosylase 1 (OGG1), Apurinic/Apyrimidinic Endonuclease 1 (APE1), and genome-wide profiling of G-quadruplex (G4) structures by Cleavage Under Targets and Tagmentation sequencing (CUT&Tag-seq). Combined with RNA-seq and ATAC-seq analysis, we performed functional validation using overexpression, RNAi, qPCR, western blot, immunofluorescence, sphere formation, and flow cytometry. High-resolution microscopy revealed that oxidized base lesions and repair complexes orchestrated the spatiotemporal dynamics of G4 structures. Co-localization of G4 structures with CpG islands (CGIs) was assessed by Whole-Genome Bisulfite Sequencing (WGBS). Finally, the therapeutic relevance of targeting this pathway was evaluated using a mouse xenograft model treated with APE1 inhibitors.
resultsWe identified the DNA base lesion repair proteins OGG1 and APE1 as key mediators of transcriptional reprogramming that promote cancer cell plasticity and resistance to EGFR-TKIs. Mechanistically, genome-wide profiling revealed their dynamic redistribution to specific genomic loci in resistant cells. Beyond canonical repair, APE1 stabilizes G4 structures at the promoters of epithelial-mesenchymal transition (EMT) and stemness-associated genes, facilitating their transcriptional activation. This APE1-driven, G4-dependent transcriptional program occurs preferentially at hypomethylated CGIs, revealing a mechanism by which DNA secondary structures shape the epigenetic landscape to promote cellular plasticity.
conclusionOur study elucidates a novel pathway in which OGG1/APE1-mediated processing of oxidative damage orchestrates a G4-dependent transcriptional program to drive EMT and stemness in EGFR-TKI-resistant NSCLC. The therapeutic potential of targeting this axis is demonstrated by the efficacy of BER inhibitors in suppressing tumor growth in vivo, establishing APE1-G4 targeting as a promising anti-resistance strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.